Grijalva Israel, Guízar-Sahagún Gabriel, Rodríguez-Pacheco Delia, Francisco-Argüelles Carlos, Castañeda-Hernández Gilberto, Palma-Aguirre José Antonio
Medical Research Unit for Neurological Diseases, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Arch Med Res. 2007 May;38(4):392-7. doi: 10.1016/j.arcmed.2006.11.007. Epub 2007 Mar 12.
4-Aminopyridine (4-AP) given to patients with chronic spinal cord injury (SCI) has shown beneficial effects in some somatic and autonomic functions, although patients often develop dyspeptic symptoms. 4-AP is a potassium-channel blocker capable of altering gastro-pyloric functions as demonstrated experimentally. Our objective was to examine the influence of 4-AP treatment on gastric emptying in patients with chronic SCI.
Gastric emptying was measured by the acetaminophen absorption test in 18 patients (9 with cervical and 9 with thoracic injury), and 9 healthy volunteers. Patients received increasing oral doses, 5 mg day(-1) of oral 4-AP (5-30 mg day(-1)), for 12 weeks. Patients were studied before and at the end of the last week of 4-AP treatment, whereas healthy volunteers (without 4-AP treatment) were studied only once. Whole blood samples of 2.5 mL were drawn at 0 (before 1 g of oral acetaminophen) and at 15, 30, 45, 60, 75, 90, 105 and 120 min postdose. Acetaminophen concentration in plasma was determined by high-pressure liquid chromatography.
Treatment with 4-AP significantly delayed stomach emptying in patients with chronic SCI, considering the significant decreasing of acetaminophen absorption (t paired test, p <0.05). This effect did not correlate either to the level or ASIA score of the injury (linear regression correlation analysis, r(2) = 0.003 and 0.015, respectively). No significant differences were observed by comparing data of patients before 4-AP treatment with healthy volunteers.
4-AP intake in patients with chronic spinal cord injury significantly slowed gastric emptying regardless of level and ASIA score of the injury.
给予慢性脊髓损伤(SCI)患者4-氨基吡啶(4-AP)已显示出对某些躯体和自主神经功能有有益作用,尽管患者常出现消化不良症状。4-AP是一种钾通道阻滞剂,实验证明它能够改变胃幽门功能。我们的目的是研究4-AP治疗对慢性SCI患者胃排空的影响。
通过对乙酰氨基酚吸收试验测量18例患者(9例颈椎损伤和9例胸椎损伤)和9名健康志愿者的胃排空情况。患者口服递增剂量的4-AP(5毫克/天(-1),口服4-AP(5-30毫克/天(-1)),持续12周。在4-AP治疗前和最后一周结束时对患者进行研究,而健康志愿者(未接受4-AP治疗)仅研究一次。在给药前(口服1克对乙酰氨基酚之前)以及给药后15、30、45、60、75、90、105和120分钟采集2.5毫升全血样本。通过高压液相色谱法测定血浆中对乙酰氨基酚的浓度。
考虑到对乙酰氨基酚吸收显著降低(配对t检验,p<0.05),4-AP治疗显著延迟了慢性SCI患者的胃排空。这种作用与损伤的水平或美国脊髓损伤协会(ASIA)评分均无相关性(线性回归相关分析,r(2)分别为0.003和0.015)。将4-AP治疗前患者的数据与健康志愿者的数据进行比较,未观察到显著差异。
慢性脊髓损伤患者摄入4-AP会显著减慢胃排空,无论损伤的水平和ASIA评分如何。